Login / Register Order My Items
Contact Us
800.227.0627
Contact Us Quote Order Login / Register
targeting ligands • receptor-mediated uptake • GalNAc leadership

Small-Molecule Targeting Ligands for Oligonucleotide Conjugates

Small-molecule targeting ligands for receptor-mediated oligonucleotide uptake, including GalNAc, folate, vitamin B12, mannose, glucose-related ligands, and bile acid-derived ligands.

Small-molecule targeting ligands enable receptor-mediated and tissue-selective delivery of therapeutic oligonucleotides, with GalNAc-based conjugates representing one of the most established targeting platforms.

GalNAcFolateVitamin B12MannoseBile acid-derived5′ modification3′ modificationsiRNAASO
Request a Quote Browse ligand categories
Talk to a chemist Request a quote
Overview Ligands at a glance Categories GalNAc platform Design guidance Advantages FAQ Milestones Reading Contact

Overview

Small-molecule targeting ligands are covalently attached to oligonucleotides to enable receptor-mediated uptake and tissue-selective delivery. These ligands guide therapeutic oligonucleotides to specific cell populations by binding surface receptors and triggering endocytosis. This strategy has become one of the most important approaches for improving pharmacokinetics, biodistribution, and cellular uptake of RNA therapeutics 4, 5.

Common ligand classes include GalNAc, folate, vitamin-derived ligands, mannose-based carbohydrates, bile-acid derivatives, and other receptor-binding small molecules. Among these, tri-GalNAc conjugates represent the most clinically validated targeting platform for hepatocyte delivery through the asialoglycoprotein receptor (ASGPR). Ligand-conjugated oligonucleotides are widely used with siRNA, antisense oligonucleotides (ASO), splice-switching oligos (SSO), and phosphorodiamidate morpholino oligos (PMO) 1–4.

As an oligonucleotide synthesis provider, we support custom synthesis and conjugation of small-molecule targeting ligands to DNA and RNA oligonucleotides, including 5′ and 3′ GalNAc or tri-GalNAc modifications, as well as other ligand architectures used in receptor-targeted oligonucleotide delivery systems.

What it does

Drives receptor-mediated uptake into selected tissues or cell types.

What it targets

ASGPR, folate receptor, mannose receptor, cobalamin-associated uptake, and other receptor-linked pathways.

What we provide

Custom ligand-modified oligos, linker design, 5′/3′ installation, purification, and QC-ready constructs.

Important distinction: Targeting ligands improve receptor-specific uptake. They do not automatically solve endosomal escape, so conjugate architecture, oligo chemistry, and trafficking behavior still matter.

Common Small-Molecule Targeting Ligands at a Glance

Ligand Primary target Typical tissue focus Common use case
Tri-GalNAc ASGPR Hepatocytes / liver Clinically validated siRNA and ASO delivery platform for liver-directed therapeutics.
Folate Folate receptor Receptor-positive tumors Tumor-targeted oligonucleotide delivery and oncology-oriented uptake studies.
Vitamin B12 Cobalamin / transcobalamin-associated uptake Liver, intestine, selected models Exploratory receptor-mediated delivery and transport biology studies.
Mannose ligands Mannose receptor (CD206) Macrophages / dendritic cells Immune-cell targeting and macrophage-oriented delivery programs.
Glucose-related ligands Transport-associated metabolic pathways Metabolically active tissues Experimental targeting strategies and tissue-uptake studies.
Bile acid-derived ligands Bile acid-associated transport biology Liver Hepatic-biased conjugates and hybrid targeting/delivery constructs.

GalNAc remains the most important and most commercially relevant ligand class on this page, but the broader ligand catalog is valuable for discovery, receptor-targeted screening, and extrahepatic delivery research.

Small-Molecule Targeting Ligand Categories

The sections below are collapsible so you can organize a broad small-molecule targeting ligand page without losing readability. GalNAc is the lead platform, but the page remains clearly focused on the full small-molecule targeting ligand landscape.

GalNAc and tri-GalNAc are the most important small-molecule targeting ligands in oligonucleotide therapeutics. They bind the ASGPR receptor on hepatocytes and drive efficient receptor-mediated liver uptake.

Feature Details
Target receptor ASGPR (highly expressed on hepatocytes)
Main tissue Liver
Common modalities siRNA, ASO, SSO, PMO and related RNA therapeutic constructs
Our capability 5′ and 3′ GalNAc or tri-GalNAc modified oligos, project-dependent linker and conjugation architecture support
Main value Clinically validated liver targeting with defined conjugate architecture
Commercial emphasis: GalNAc / tri-GalNAc modification is a core and high-value platform. If the page is meant to sell what matters most, this should remain the most detailed section.

Folate is a classic small-molecule targeting ligand used to engage folate receptors, especially in receptor-positive tumor models. Folate-conjugated oligonucleotides are relevant to oncology delivery strategies, targeted uptake studies, and ligand-directed probe design.

  • Common use: receptor-positive cancer targeting
  • Typical architecture: oligonucleotide – spacer – folate
  • Design caution: receptor expression varies strongly across tumor types

Vitamin B12-based ligands exploit cobalamin-associated uptake biology and are relevant to exploratory receptor-mediated oligonucleotide delivery. These ligands are less mature than GalNAc, but they remain valuable in transport-biology-driven delivery programs.

  • Potential value: receptor-associated uptake and transport pathway exploitation
  • Typical use: exploratory siRNA or ASO delivery studies
  • Design caution: conjugation must preserve recognition features

Mannose ligands are used for targeting mannose receptor-positive immune cells, including macrophages and dendritic cells. These constructs are useful when the project goal is immune-cell delivery rather than hepatocyte targeting.

  • Typical targets: CD206-positive macrophage and dendritic cell populations
  • Application area: immunology, inflammatory disease, and vaccine-related delivery concepts
  • Design caution: valency often influences performance

Glucose-related ligands and related sugar-based motifs are part of an experimental targeting category built around metabolic uptake bias and transporter-linked tissue behavior. These are more exploratory than GalNAc or folate but are still useful for a comprehensive targeting-ligand page.

  • Typical use: experimental tissue targeting studies
  • Main value: chemically accessible small-molecule targeting concept
  • Design caution: uptake pathways may be less selective than receptor-targeted systems

Bile acid-derived ligands such as cholic acid and related structures can support liver-oriented conjugate strategies. Depending on architecture, they may behave partly as targeting ligands and partly as delivery-biased small molecules.

  • Typical use: hepatic-biased uptake studies and hybrid targeting/delivery constructs
  • Main value: liver-relevant transport biology and conjugate design flexibility
  • Design caution: less receptor-specific than tri-GalNAc

GalNAc / Tri-GalNAc Oligo Platform

Because GalNAc is the most clinically validated small-molecule targeting ligand platform, it is often discussed separately in dedicated pages focused on GalNAc oligonucleotide conjugates and liver-targeted RNA therapeutics. On this hub page, GalNAc / tri-GalNAc is presented as the lead example within the broader small-molecule targeting ligand landscape. We support GalNAc and tri-GalNAc modified oligos at both the 5′ and 3′ terminus, with architecture tailored to modality, linker strategy, and downstream application.

Tri-GalNAc Oligonucleotide Conjugate Architecture

Tri-GalNAc oligonucleotide conjugate structure showing three N-acetylgalactosamine ligands attached through linker architecture to the oligonucleotide 3′ terminus
Example structure of a tri-GalNAc–oligonucleotide conjugate showing the multivalent GalNAc ligand cluster connected through linker architecture to the oligonucleotide.

For detailed architecture and conjugation strategies, see our GalNAc oligonucleotide conjugation platform.

5′ GalNAc / tri-GalNAc

Terminal targeting-ligand installation for project-specific architectures, including receptor-targeted screening constructs and therapeutic-format oligos.

3′ GalNAc / tri-GalNAc

Common terminal architecture for siRNA and related constructs when receptor presentation and oligo function must be balanced.

Linker & spacer options

Project-dependent linker design to preserve receptor engagement, reduce steric interference, and support clean purification.

Parameter Why it matters
Ligand valency Tri-GalNAc improves receptor engagement and remains the best-validated architecture for ASGPR-driven uptake.
Attachment site 5′ or 3′ placement can influence receptor presentation, duplex function, and assay behavior.
Spacer design Controls steric presentation and can materially affect uptake and purification performance.
Modality fit siRNA, ASO, SSO, and PMO may require different installation logic and structure-activity evaluation.

Design Guidance for Small-Molecule Targeting Ligand Conjugates

Receptor biology

The best ligand is the one matched to the biology of the intended tissue. Receptor density, recycling, and endocytic route all matter.

Spacer & sterics

Spacer length affects ligand accessibility and can reduce steric interference between the oligo and the receptor-binding moiety.

Intracellular trafficking

A targeting ligand can increase uptake without producing functional activity unless intracellular trafficking and endosomal release are also favorable.

Practical development logic: evaluate ligand class, attachment site, spacer length, and oligo chemistry as a matched design set rather than as isolated variables.

Why Small-Molecule Targeting Ligands Matter

Advantages
  • Low molecular weight and reduced steric burden
  • Defined conjugate architecture
  • Scalable chemical synthesis and conjugation
  • Cleaner analytics than larger targeting systems
  • Compatible with modular oligonucleotide workflows
What to remember
  • Targeting ligands improve uptake bias, not necessarily intracellular release
  • Receptor expression and biology determine real performance
  • GalNAc leads clinically, but broader ligand classes are still important for a complete platform offering

Key Clinical Milestones in Ligand-Targeted Oligonucleotides

Ligand-targeted oligonucleotide delivery has moved from receptor-targeting concept to clinically validated therapeutic strategy. The timeline below highlights how GalNAc-based targeting helped establish small-molecule ligand conjugation as a major delivery platform in RNA therapeutics.

Early translational phase
  • 2010s: multivalent GalNAc conjugates demonstrated efficient ASGPR-mediated hepatocyte delivery in preclinical systems.
  • Mechanistic shift: receptor-targeted oligo uptake became a defined alternative to non-targeted carrier systems.
  • Platform lesson: ligand valency, attachment site, and linker presentation strongly influenced productive uptake.
Clinical validation phase
  • Approved GalNAc-siRNA medicines established small-molecule targeting ligands as a clinically proven delivery approach.
  • Commercial impact: GalNAc became the lead example for receptor-targeted oligonucleotide conjugates.
  • Field expansion: folate, mannose, vitamin-derived ligands, and other receptor-targeting motifs remain important for extrahepatic and exploratory programs.
Takeaway: This page covers the broader small-molecule targeting ligand landscape, while GalNAc remains the most clinically validated and commercially mature example within that category.

FAQ

What is a small-molecule targeting ligand in oligonucleotide conjugation?

A small-molecule targeting ligand is a low-molecular-weight receptor-binding moiety covalently attached to an oligonucleotide to increase tissue- or cell-selective uptake through receptor-mediated endocytosis.

Is GalNAc a targeting ligand or a delivery modifier?

GalNAc is best classified as a targeting ligand because it drives hepatocyte-selective uptake through ASGPR receptor binding. In site architecture, it often has its own dedicated service page while also appearing within broader targeting-ligand hub content.

Do you provide GalNAc-modified oligos at both 5′ and 3′ termini?

Yes. We provide GalNAc and tri-GalNAc modified oligos at both the 5′ and 3′ terminus, with project-dependent linker and architecture options for siRNA, ASO, SSO, PMO and related constructs.

Do targeting ligands solve endosomal escape?

Not necessarily. Targeting ligands improve receptor-mediated uptake, but intracellular trafficking and endosomal release still need to be considered separately during conjugate design.

More FAQ'sAll FAQ's

Contact & Project Scoping

For the fastest review, share your oligonucleotide modality, preferred targeting ligand, desired installation site (5′ or 3′), and whether you need a standard or custom spacer/linker architecture.

Typical scoping inputs
  • Modality: siRNA / ASO / SSO / PMO / RNA probe
  • Ligand class: GalNAc, tri-GalNAc, folate, mannose, vitamin B12, bile acid-derived
  • Attachment site: 5′ / 3′ / project-dependent
  • Spacer preference: PEG / alkyl / custom
Priority platform

If your project is liver-directed, ask specifically about GalNAc / tri-GalNAc modified oligos at 5′ or 3′, since that is the most mature and commercially important targeting ligand category on this page.

Request a quoteOligonucleotide conjugation overview

Recommended Reading

The following literature highlights the development of receptor-targeted oligonucleotide delivery systems using small-molecule ligands such as GalNAc, folate, and other receptor-binding conjugates. These studies helped establish ligand-mediated uptake as a central strategy in RNA therapeutics.

Ligand-Targeted Oligonucleotide Delivery
  • Nair, J. K., et al. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and improves RNAi-mediated gene silencing. Journal of the American Chemical Society, 136, 16958-16961.
  • Prakash, T. P., et al. (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary GalNAc conjugates. Journal of Medicinal Chemistry, 57, 8758-8769.
  • Springer, A. D., & Dowdy, S. F. (2018). GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Therapeutics, 28, 109-118.
Oligonucleotide Delivery & Targeting Strategies
  • Roberts, T. C., Langer, R., & Wood, M. J. A. (2020). Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery, 19, 673-694.
  • Juliano, R. L. (2016). The delivery of therapeutic oligonucleotides: obstacles and opportunities. Nucleic Acids Research, 44, 6518-6548.
  • Khvorova, A., & Watts, J. K. (2017). The chemical evolution of oligonucleotide therapies of clinical utility. Nature Biotechnology, 35, 238-248.

These references provide foundational background on receptor-mediated uptake, GalNAc-based targeting, and the broader chemical evolution of ligand-conjugated oligonucleotide therapeutics.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links